Has Steven Pipe, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,321,274 in general payments to Steven Pipe, MD across 774 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Pipe, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Pipe, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Pipe, MD

Pediatric Hematology-Oncology · Ann Arbor, MINPI 1255341889

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.9%. Among pediatric hematology-oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,321,274in general payments, 2019–2025

Across 774 payments — averaging $1707.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

CSL Behring$250K
Sanofi$200K
Biomarin Pharmaceutical Inc.$147K
HEMA Biologics, LLC$142K
Novo Nordisk$74K
Pfizer$73K
plus $436K from 20 others

$2,320,856in research payments, 2019–2025

Across 489 payments — averaging $4746.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$482K
CSL Behring$331K
Biomarin Pharmaceutical Inc.$327K
Regeneron$227K
Sanofi$167K
Sanofi US Services Inc.$166K
plus $620K from 9 others

What the payments were for

Consulting fees$656,05050%
Speaking & faculty fees$450,89234%
Grants$6930%
Travel & lodging$200,65915%
Food & beverage$11,5871%
Education$1,3570%
Gifts$360%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
CSL Behring	179	$249,802
Sanofi	79	$199,864
Biomarin Pharmaceutical Inc.	70	$147,469
HEMA Biologics, LLC	137	$141,868
Novo Nordisk	30	$73,837
Pfizer	41	$72,836
Novo Nordisk Health Care AG	14	$45,428
Spark Therapeutics, Inc.	14	$44,734
Roche Products Limited	14	$41,785
Genentech USA, Inc.	52	$37,515
Sanofi-aventis U.S. LLC	9	$36,495
Chugai Pharmaceutical Co., Ltd.	12	$34,668
Regeneron	28	$34,403
Ultragenyx Pharmaceutical Inc.	7	$32,191
F. Hoffmann-la Roche AG	22	$25,884
Takeda Pharmaceuticals U.S.A., Inc.	12	$24,646
Hoffmann-la Roche Limited	6	$16,553
Sanofi US Services Inc.	3	$15,892
Bioverativ Therapeutics Inc.	19	$12,727
Swedish Orphan Biovitrum AB	2	$9,900
Novo Nordisk AS	2	$5,400
Genentech, Inc.	3	$4,351
Samsung Bioepis Co., Ltd.	2	$4,000
Shire North American Group Inc	1	$3,938
Siemens Medical Solutions USA, Inc.	14	$3,054
Bayer	2	$2,034

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SevenFact$138,858
HEMGENIX$88,309
HEMLIBRA$62,725
NovoSeven$20,390
Idelvion$19,085
HYMPAVZI$17,750
Roctavian$16,687
Afstyla$15,697
ADVATE$14,500
NovoSeven RT$14,025
FEIBA$12,546
BENEFIX$11,100
ADYNOVATE$7,500
FITUSIRAN$7,195
Novoeight$4,430
NO PRODUCT DISCUSSED$3,843
VONVENDI$3,600
BEQVEZ$2,000
SB39$2,000
ELOCTATE$1,359

How this compares

$1,321,274 in reported general payments places this provider in the 95th percentile of 84 pediatric hematology-oncology providers in Michigan.

See all pediatric hematology-oncology providers in Michigan →

Medicare billing

Part B allowed, 2024

$3,211

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric hematology-oncology in Ann Arbor

Angela WeyandAnn Arbor$384K
Jordan ShavitAnn Arbor$190K
Andrew CampbellAnn Arbor$94K
Kelly WalkovichAnn Arbor$43K
Rajen ModyAnn Arbor$24K
Andrea FransonAnn Arbor$18K
Patrick GroharAnn Arbor$8K
Ghada AbusinAnn Arbor$4K
Gregory YanikAnn Arbor$3K
Sharon SinghAnn Arbor$2K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →